Tema Etfs LLC Makes New Investment in Masimo Co. (NASDAQ:MASI)

Tema Etfs LLC bought a new position in shares of Masimo Co. (NASDAQ:MASI - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,580 shares of the medical equipment provider's stock, valued at approximately $1,584,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Masimo by 19.8% in the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after buying an additional 1,340,836 shares during the period. Capital Research Global Investors increased its position in shares of Masimo by 80.5% in the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after purchasing an additional 1,094,647 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Masimo by 119.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock valued at $286,823,000 after purchasing an additional 943,001 shares during the last quarter. Alliancebernstein L.P. lifted its position in shares of Masimo by 1,276.9% during the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock worth $156,604,000 after purchasing an additional 878,587 shares during the last quarter. Finally, Corient Private Wealth LLC grew its stake in shares of Masimo by 8,847.1% during the fourth quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider's stock worth $57,472,000 after purchasing an additional 343,797 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Analysts Set New Price Targets

MASI has been the subject of a number of research analyst reports. Wells Fargo & Company lowered their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and issued a $200.00 price target (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. BTIG Research set a $193.00 price objective on shares of Masimo and gave the company a "buy" rating in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Finally, Raymond James lowered their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $191.60.

Insiders Place Their Bets

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. This trade represents a 55.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,053 shares of company stock worth $6,998,565 over the last quarter. 16.90% of the stock is owned by corporate insiders.

Masimo Price Performance

Shares of NASDAQ:MASI traded down $1.21 on Friday, hitting $148.71. The company had a trading volume of 76,004 shares, compared to its average volume of 650,970. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market cap of $8.06 billion, a PE ratio of 102.39 and a beta of 1.23. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The business has a 50 day moving average of $158.78 and a 200 day moving average of $167.39.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. During the same quarter in the previous year, the business posted $0.77 earnings per share. The company's revenue was down 24.5% on a year-over-year basis. As a group, equities analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.